In this context, the detection of the BRAF V600E mutation opens the door to an agnostic approach based on targeted therapies, such as BRAF inhibitors, which are effective in other malignancies like melanoma, colorectal cancer, and certain thyroid tumors [9]. This evidence concerns the gene BRAF and melanoma.